Related Experiment Video
Updated: May 3, 2026
High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
Published on: March 22, 2011
Suppression effect of recombinant adenovirus vector containing hIL-24 on Hep-2 laryngeal carcinoma cells
Xuemei Chen1, DI Liu2, Junfu Wang3
1Department of Otolaryngology, The Second Affiliated Hospital of Shandong University, Jinan, Shandong 250033, P.R. China.
Abstract:
The melanoma differentiation-associated gene-7 [MDA-7; renamed interleukin (IL)-24] was isolated from human melanoma cells induced to terminally differentiate by treatment with interferon and mezerein. MDA-7/IL-24 functions as a multimodality anticancer agent, possessing proapoptotic, antiangiogenic and immunostimulatory properties. All these attributes make MDA-7/IL-24 an ideal candidate for cancer gene therapy. In the present study, the human MDA-7/IL-24 gene was transfected into the human laryngeal cancer Hep-2 cell line and human umbilical vein endothelial cells (HUVECs) with a replication-incompetent adenovirus vector. Reverse transcription polymerase chain reaction and western blot analysis confirmed that the Ad-hIL-24 was expressed in the two cells. The expression of the antiapoptotic gene, Bcl-2, was significantly decreased and the IL-24 receptor was markedly expressed in Hep-2 cells following infection with Ad-hIL-24, but not in HUVECs. In addition, the expression of the proapoptotic gene, Bax, was induced and the expression of caspase-3 was increased in the Hep-2 cells and HUVECs. Methyl thiazolyl tetrazolium assay indicated that Ad-hIL-24 may induce growth suppression in Hep-2 cells but not in HUVECs. In conclusion, Ad-hIL-24 selectively inhibits proliferation and induces apoptosis in Hep-2 cells. No visible damage was found in HUVECs. Therefore, the results of the current study indicated that Ad-hIL-24 may have a potent suppressive effect on human laryngeal carcinoma cell lines, but is safe for healthy cells.
Insights
Interleukin-24 (IL-24) delivered via adenovirus selectively targets laryngeal cancer cells, inducing apoptosis and inhibiting growth while sparing healthy cells. This gene therapy shows promise for treating laryngeal carcinoma safely.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Melanoma differentiation-associated gene-7 (MDA-7), now known as interleukin-24 (IL-24), exhibits anticancer properties including apoptosis induction and antiangiogenesis.
- MDA-7/IL-24's multimodal action makes it a potential candidate for cancer gene therapy.
Purpose of the Study:
- To investigate the efficacy and safety of delivering the human IL-24 gene (hIL-24) using an adenovirus vector (Ad-hIL-24) in human laryngeal cancer cells (Hep-2) and human umbilical vein endothelial cells (HUVECs).
Main Methods:
- Transfection of Ad-hIL-24 into Hep-2 cells and HUVECs.
- Confirmation of gene expression using reverse transcription polymerase chain reaction and western blot.
- Analysis of apoptosis-related gene expression (Bcl-2, Bax) and caspase-3 activity.
- Cell proliferation assessment using methyl thiazolyl tetrazolium assay.
Main Results:
- Ad-hIL-24 expression was confirmed in both Hep-2 cells and HUVECs.
- In Hep-2 cells, Ad-hIL-24 decreased Bcl-2 expression, increased Bax and caspase-3 expression, and induced apoptosis, leading to growth suppression.
- HUVECs showed increased Bax and caspase-3 expression but no significant growth inhibition or visible damage, suggesting selective toxicity.
Conclusions:
- Ad-hIL-24 demonstrates selective inhibition of proliferation and induction of apoptosis in human laryngeal carcinoma Hep-2 cells.
- The Ad-hIL-24 vector appears safe for healthy cells like HUVECs, indicating potential for targeted laryngeal cancer gene therapy.
